placulumab
mAbexperimental
Placulumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00854685)
Timeline
Indications
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPlaculumab ↗
- ChEMBLCHEMBL2108739 ↗
Also known as
- art621
- art621
- cep-37247
- cep-37247
- placulumab
- placulumab
- pn-0621
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01240876 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | Cephalon |
| NCT00928317 | Phase 2 | Apr 1, 2009 | Arana Therapeutics Ltd |
| NCT00854685 | Phase 2 | Feb 1, 2009 | Arana Therapeutics Ltd, Trident Clinical Research Pty Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arana Therapeutics Ltd | For profit | 2 | 2 | 1 | 2009 |
| Cephalon | For profit | 1 | 1 | 1 | 2011 |
| Trident Clinical Research Pty Ltd | For profit | 1 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1